Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS
https://unsplash.com/photos/_jbClosDsD4

Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS

In a news release from July 21, 2021, biotechnology company Genentech shared that its therapy Venclexta (venetoclax), in conjunction with azacitidine, received Breakthrough Therapy designation from the FDA. Overall, the…

Continue Reading Venclexta with Azacitidine Granted Breakthrough Therapy Designation for MDS
First Patient Dosed in CA-4948 Trial for Hematologic Malignancies
source: pixabay.com

First Patient Dosed in CA-4948 Trial for Hematologic Malignancies

The first patient has been dosed in a Phase 1 clinical trial, which is exploring Curis Inc.'s CA-4948 in conjunction with ibrutinib for hematologic malignancies. Examples of hematologic malignancies include…

Continue Reading First Patient Dosed in CA-4948 Trial for Hematologic Malignancies
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors
source: pixabay.com

Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors

Poly (ADP-Ribose) polymerase inhibitors (PARP inhibitors) are used to treat neoplasms. They are frequently used as a therapy for ovarian cancer. A recent study has attempted to detect the possibility…

Continue Reading Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia May Increase with PARP Inhibitors

Sabatolimab Can Be Added Safely to Hypomethylating Agents in the Treatment of MDS and AML

Dr. Andrew Brunner, an oncologist at Massachusetts Cancer Center was recently interviewed by Targeted Oncology. The discussion centered around a phase 1b clinical trial (NCT03066648) investigating sabatolimab together with hypomethylating…

Continue Reading Sabatolimab Can Be Added Safely to Hypomethylating Agents in the Treatment of MDS and AML
Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
source: pixabay.com

Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers

While novel treatments have been rapidly emerging onto the drug scene, new treatment options for pancreatic cancer have fallen behind. But now, according to OncLive’s interview with Dr. P.A. Philip,…

Continue Reading Experimental Treatment Could be Useful in Numerous Rare and Deadly Cancers
50% Enrollment Reached in Imetelstat Trial for MDS
source: pixabay.com

50% Enrollment Reached in Imetelstat Trial for MDS

Since its conception, biopharmaceutical company Geron Corporation ("Geron") has worked to develop first-in-class therapies for hematologic myeloid malignancies. More recently, Geron began evaluating imetelstat for patients with lower risk myelodysplastic syndromes…

Continue Reading 50% Enrollment Reached in Imetelstat Trial for MDS
Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response
source: pixabay.com

Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response

According to a story from Hematology Advisor, a recent study released in Scientific Reports indicates that gene expression has the potential to predict both primary resistance and treatment response in patients living…

Continue Reading Myelodysplastic Syndromes: Gene Expression Could Predict Azacitidine Response
UT Southwestern Expands Diagnostic and Treatment Approaches for Aplastic Anemia, MDS
source: pixabay.com

UT Southwestern Expands Diagnostic and Treatment Approaches for Aplastic Anemia, MDS

What are the best treatments and diagnostic approaches for blood disorders like aplastic anemia and myelodysplastic syndromes (MDS)? The UT Southwestern Medical Center is trying to streamline these options and…

Continue Reading UT Southwestern Expands Diagnostic and Treatment Approaches for Aplastic Anemia, MDS
Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment
source: pixabay.com

Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment

Historically, clinical trials have played an immense role in collecting patient data, understanding disease progression, and crafting more targeted treatments. This is especially true in the oncology realm. But according…

Continue Reading Difficulty Finding MDS Treatments Linked to Low Clinical Trial Enrollment
September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness
source: pixabay.com

September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness

September 15th, 2020 is recognized as World Lymphoma Awareness Day. This day is dedicated to spreading awareness about lymphoma and falls in the context of Blood Cancer Awareness Month, which…

Continue Reading September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness
2 TP53 Mutations Worsen Blood Cancer Severity, Says Study
source: pixabay.com

2 TP53 Mutations Worsen Blood Cancer Severity, Says Study

Recently, the MDS Foundation announced that two TP53 gene mutations result in worse patient outcomes in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). According to their international and multi center study,…

Continue Reading 2 TP53 Mutations Worsen Blood Cancer Severity, Says Study
Can Rigosertib Change the Myelodysplastic Syndromes Treatment Landscape?
source: pixabay.com

Can Rigosertib Change the Myelodysplastic Syndromes Treatment Landscape?

By Lauren Taylor from In The Cloud Copy Onconova Therapeutics, Inc. is a biopharmaceutical company that works to develop new drugs to treat cancer, primarily focusing on myelodysplastic syndromes. Myelodysplastic…

Continue Reading Can Rigosertib Change the Myelodysplastic Syndromes Treatment Landscape?